Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 8 Neoplasms 4 Neoplasm Metastasis 3 Lung Neoplasms 3 Hematologic Neoplasms 3 Neoplasms by Site 2 Neoplasms by Histologic Type 2 Lymphoproliferative Disorders 2 Lymphoma, Large-Cell, Anaplastic 2 Sexual Dysfunction, Physiological 1 Rare Tumor 1 Neuroblastoma 1 Lymphoma 1 Lung Diseases 1 Eunuchism 1 Erectile Dysfunction 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Brain Neoplasms 1

Interventions

Bevacizumab 77 Fluorouracil 55 Cetuximab 48 Oxaliplatin 43 Leucovorin 42 pembrolizumab 37 Irinotecan 33 Folfox protocol 24 Capecitabine 24 HMPL-013 22 Specimen Handling 19 trifluridine tipiracil drug combination 17 Panitumumab 15 Blood Specimen Collection 15 Nivolumab 14 Magnetic Resonance Spectroscopy 14 regorafenib 13 Biopsy 13 Trifluridine 12 Gemcitabine 12 Cisplatin 12 Standard of Care 11 sintilimab 10 Interviews as Topic 10 IFL protocol 10 Drug Therapy 10 Carboplatin 10 Cyclophosphamide 9 tislelizumab 8 Trastuzumab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Colorectal Neoplasms × alectinib × Clear all

NCT05725200 2023-02-21

EVIDENT

Oslo University Hospital

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡